Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report), Artelo Biosciences (ARTL – Research Report) and Siemens Healthineers AG (SEMHF – Research Report).
Roche Holding AG (RHHVF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG, with a price target of CHF265.00. The company’s shares closed last Thursday at $301.34, close to its 52-week low of $299.01.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Roche Holding AG with a $379.84 average price target, which is a 25.9% upside from current levels. In a report issued on January 19, J.P. Morgan also maintained a Sell rating on the stock with a CHF275.00 price target.
See today’s best-performing stocks on TipRanks >>
Artelo Biosciences (ARTL)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Artelo Biosciences, with a price target of $60.00. The company’s shares closed last Thursday at $3.08, close to its 52-week low of $2.38.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Artelo Biosciences with a $41.67 average price target, implying a 1239.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $55.00 price target.
Siemens Healthineers AG (SEMHF)
Deutsche Bank analyst Falko Friedrichs maintained a Buy rating on Siemens Healthineers AG today and set a price target of EUR64.00. The company’s shares closed last Friday at $53.00.
According to TipRanks.com, Friedrichs is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Siemens Healthineers AG with a $64.66 average price target, which is a 23.7% upside from current levels. In a report issued on January 25, UBS also maintained a Buy rating on the stock with a EUR59.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
- [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
- Roche reports EC approves label expansion of Hemlibra
- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
- Roche price target lowered to CHF 350 from CHF 380 at Berenberg
